• Managed/mentored client strategy team to ensure research findings always translated into actionable strategies, enhanced client satisfaction, and generated new and repeat revenue.
• Responsible for re-invigorating several accounts that were not healthy, grew sales in 2024 by 10% and in 2025 acquired MSAs for 3 new logos.
• Leveraged two new AI offerings to open discussions at 3 new accounts and supported adoption of AI in various research operations at KJT.
• Participated as a member of the Executive Team, led implementation of new corporate structure to better service our clients and developed formalized solution offerings to support sales efforts.

• Developed a formalized Health unit at tech start-up.
• Developed critical research-on-research study to demonstrate key benefits of R3s Conversational Insights platform among patients and physicians.
• Onboarded 2 pharma companies (w/MSA), 3 hospital systems and 2 insurers.
• Sales of ~950K in first year of Health unit beating target of $750K.

• Responsible for re-invigorating growth after 4 years of flat revenue, first full year of 2021 resulted in 22% growth of the division.
• Re-developed Health strategy to focus on leveraging Phoenix's advertising products as an entrée into several new clients, 5 MSAs were signed/renewed in 2021.
• Served as senior consultant on multiple key strategic client initiatives resulting in presentations to executive level teams and an RWE publication.

Escalent (formerly Market Strategies) July 2018 – June 2020
• Participated in the merger of Market Strategies and Morpace as a member of the Executive Team to identify redundancies and gaps in the combined organizations
• Led integrated Health team, leveraging change management.
• Implemented workforce optimization initiatives by evaluating team skillsets and aligning resource allocation with business needs during onset of COVID.

• Led the standardization of modular solution packages to prepare the organization's transaction readiness.
• Assumed management and oversight of the Marketing Science Team, Center of Qualitative Excellence.
• Continued management of the Health team in coordination with two team SVP leaders.

• Promoted to SVP with oversight of Pharma business within Health team. Progressed to oversight of entire Health unit including systems and insurer along with pharma sector (~50 individuals, $18 in sales).
• Owned Health P&L and developed annual business plans. Achieved 8-10% profit annually and annual
● growth of 5-8%.
• Participated as a member of Leadership Team and advanced to Executive Team in 2013.

• Managed the Midwest pharma research team (10 individuals).
• Expanded portfolio from one key client into several other pharma and device companies, driving growth from $850K to $8M.
• Created the first qualitative market research function at MSI, hiring two FTE trained moderators to Health team.

• Supported clinical development and portfolio management of duloxetine (Cymbalta),
● fluoxetine and olanzapine/fluoxetine by providing global market insights.
• Developed product forecasts that fed into commercial decision of Cymbalta vs.
● fluoxetine.

• Evaluated potential acquisition targets through scenario analysis and competitive landscape reviews for pharmaceutical clients.
• Designed and implemented Excel-based forecasting tools to estimate patient populations for new prescription drug candidates, using advanced quantitative analytics to inform product commercialization decisions.